Physician profile
Sunil D Kumar
NPI 1972787836
$4,267.63
in general payments reported to CMS, 2019-2025
27 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $226 · 2021: $407 · 2022: $791 · 2023: $493 · 2024: $572 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.00 |
| Education | $140.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $469.01 | 2023-2025 | Ensite Precision, Aveir, Gallant |
| Astrazeneca Pharmaceuticals Lp | $455.23 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $432.58 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $401.78 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $323.03 | 2020-2024 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $318.43 | 2019-2025 | Trelegy Ellipta, Nucala |
| Biosense Webster, INC. | $205.47 | 2024 | Nuvision Ice Catheter |
| Merck Sharp & Dohme LLC | $192.48 | 2019-2025 | Zerbaxa, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $153.34 | 2019-2025 | Uptravi, Opsumit |
| Alexion Pharmaceuticals, INC. | $153.22 | 2022-2024 | Ultomiris |
| United Therapeutics Corporation | $143.43 | 2021-2022 | |
| Boston Scientific Corporation | $133.58 | 2022 | |
| Abiomed | $130.08 | 2020 | |
| Allergan, INC. | $120.74 | 2019 | |
| Abbvie INC. | $108.79 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $88.74 | 2019 | |
| Pfizer INC. | $84.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.07 | 2019 | |
| La Jolla Pharmaceutical Company | $57.68 | 2019-2021 | |
| Melinta Therapeutics, LLC | $50.42 | 2023-2025 | Rezzayo, Vabomere |
| Mylan Specialty L.P. | $47.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $44.55 | 2022 | |
| Medtronic, INC. | $22.10 | 2023 | Micra |
| Bayer Healthcare Pharmaceuticals INC. | $19.91 | 2024 | |
| Insmed, INC. | $19.05 | 2025 | Arikayce |
| Zoll Circulation INC | $16.85 | 2023 | Temperature Management System Start-Up Kit, Catheter, Temperature Management System |
| Paratek Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.